Latest Us Army News

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Pointerra Limited reported strong FY25 Q4 results marked by new enterprise customers, a major US defense subcontract, and significant cashflow improvements. The company’s AI-enhanced digital twin platform is gaining traction across multiple sectors, setting the stage for growth in FY26.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.

Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

Pointerra Limited has joined forces with Leidos as a subcontractor on the US Army’s $499 million GRIDS IV program, aiming to enhance real-time geospatial intelligence through advanced AI and machine learning technologies.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.